Development of novel therapeutic strategies is a continuing challenge for the treatment of acute myeloid leukemia (AML). The novel triterpenoid, C-28 methyl ester of 2-cyano-3,12-dioxoolen-1,9-dien-28-oic acid (CDDO-Me), induces apoptosis in myeloid leukemic cell lines and in primary AML samples. In this report, the effects of CDDO-Me on CD34
Introduction
The mitogen-activated protein kinase (MAPK) family of enzymes regulates multiple signaling pathways that control diverse biological processes including cell proliferation, cell cycle, and programmed cell death. [1] [2] [3] [4] Normal hematopoietic cells rely on MAPK signaling cascades that are initiated by cytokines (eg IL-3-mediated in myeloid cells) and involve Ras/Raf/MEK/ERK for normal cell proliferation. 4 While the list of ERK substrates is far from complete, a number of ERK targets have been identified that play critical roles in important biological processes such as transcription (eg Elk1, c-Fos 3, 5 ), apoptosis (eg Bcl2 6 ), cell metabolism (eg phosphodiesterase 3, 7 ) , and cell adhesion (eg paxillin 3, 8 ). The dysregulation of MAPK pathways appears to be an important factor in leukemogenesis and chemoresistance in acute myeloid leukemia (AML). [9] [10] [11] [12] [13] [14] In two clinical studies, ERK activity was found to be elevated in the majority of blast cells from AML patients studied 9, 12 and was associated with poor prognosis in multivariate analysis (Kornblau et al Blood 2001; 98: 716a, abstract). The identification of ERK substrates that might contribute to ERK-regulated leukemogenesis or chemoresistance is unknown; however, a role for Bcl2 in ERK-mediated chemoresistance in AML is likely since gain-of-function Bcl2 mutants that mimic phosphorylation of serine 70 (the residue targeted by ERK) protect AML-derived cell lines such as HL60 and U937 and factor dependent murine myeloid cells from apoptosis induced by chemotherapeutic agents such as etoposide and araC, IL-3 growth factor withdrawal, or treatment with ceramide. 6, 15, 16 Triterpenoid drugs, including C-28 methyl ester of 2-cyano-3,12-dioxoolen-1,9-dien-28-oic acid (CDDO-Me), have proved to be effective agents in killing cancer cells and are potentially new agents for antineoplastic strategies for leukemia, multiple myeloma, and solid tumor cancers such as breast cancer. [16] [17] [18] [19] [20] [21] CDDO-Me has been shown to (a) promote apoptosis in a number of leukemic cell lines (eg U937 and HL60), (b) induce pro-apoptotic Bax protein as a prelude to caspase activation, and (c) suppresse the activation of ERK1/2 with concomitant inhibition of Bcl-2 phosphorylation. 16 Considering the important role that ERK plays in leukemogenesis and chemoresistance, CDDO-Me inhibition of ERK may be critical for the proapoptotic properties of the drug. In this study, the ability of CDDO-Me to promote apoptosis and suppress ERK phosphorylation (ie activation) was assessed in primary blast cells derived from patients with AML. While CDDO-Me was potent at inducing apoptosis and inhibiting ERK phosphorylation in the majority of blast cells tested, a number of cases were found to undergo apoptosis independent of ERK. This finding raised the possibility that other pathways might be involved in CDDO-Meinduced apoptosis. The stress-activated protein kinase (SAPK) family of proteins contains MAPK family members that are activated in response to stress stimuli rather than mitogens or cytokines.
1,2 SAPK members such as JNK have been shown in some cases to be oppositely regulated to ERK. 22 Such a regulatory mechanism raises the possibility that CDDO-Me might activate SAPK enzymes while suppressing the MAPK pathway. Activation of JNK by CDDO-Me has been demonstrated, 21 though the consequences of this phenomenon to cell survival in primary AML cells are unknown. Therefore, effects of inhibition of JNK and p38 on CDDO-Me-induced apoptosis in U937 cells were examined. Results indicate that CDDO-Me promotes p38 phosphorylation.
Materials and methods

Cell lines and blast cells
U937 cells were obtained from the ATCC (Rockville, MD, USA) and maintained in RPMI 1640 þ 10% fetal bovine serum at 371C in 5% CO 2 . Samples of bone marrow or peripheral blood were obtained for in vitro studies from patients with newly diagnosed or recurrent AML with high (more than 40%) blast count. Informed consent was obtained following institutional guidelines. Clinical data for AML patients are presented in Table 1 . Analysis of apoptosis by annexin V staining U937 cells or blast cells were treated with varying doses of CDDO-Me for 24 h and viability was assessed by PS/annexin V analysis as previously described. 23 For two-color flow cytometry used for primary AML samples, the PE-conjugated antiCD34 monoclonal antibody (Becton Dickinson, San Jose, CA, USA) was used at 1:10 dilution. Where appropriate, cells were pretreated with JNK inhibitor (SP600125, Calbiochem) or p38 inhibitor (SB203580, Calbiochem). Cells were washed in PBS, resuspended in binding buffer containing annexin V (Roche Diagnostics, Indianapolis, IN, USA) and analyzed by flow cytometry using a Becton Dickinson FACScan after the addition of propidium iodide (Sigma).
Cytofluorometric analysis of mitochondrial membrane potential
To determine mitochondrial membrane potential, cells treated with 1 mM CDDO-Me for 24 h were incubated with cationic lipophilic dye chlorophenyl-X-rosamine (CMXRos; Molecular Probes, Eugene, OR, USA) and Mitotracker Green (Molecular Probes). Fluorescence was determined by FACScan as previously described. 16 
Western blot analysis
Cells were sonicated in lysis buffer (62.5 mM Tris (pH 8.0), 2% SDS, 10% glycerol, 100 mM AEBSF, 80 nM aprotinin, 5 mM bestatin, 1.5 mM E-64, 2 mM leupeptin, 1 mM pepstatin, 500 mM sodium orthovanadate, 500 mM glycerol phosphate, 500 mM sodium pyrophosphate, and 50 mM DTT) and protein (5 Â 10 5 cell equivalents) was subjected to electrophoresis using 10-14% acrylamide/0.1% SDS gels. Proteins were transferred to a nitrocellulose membrane and Western blotting analysis was performed with antibodies against ERK and phospho-ERK (Cell Signaling, Beverly, MA, USA), JNK and phospho-JNK (Cell Signaling, Beverly, MA, USA), p38 and phospho-p38 (Cell Signaling, Beverly, MA, USA), GAPDH (Chemicon International, Temecula, CA, USA), and tubulin (Sigma). Western blots were developed using an ECL kit (Amersham, Piscataway, NJ, USA).
For quantitation, gels were analyzed using the Scion Image software. Integrated optical density of each lane (band obtained with the phospho-specific antibody) was recorded and compared to the optical density of the band obtained with the total antibody of the same sample.
Results
CDDO-Me promotes apoptosis and suppresses ERK phosphorylation in the majority of AML
CDDO-Me can potently promote apoptosis in human AML cell lines with concomitant inhibition of ERK. 16 In vitro treatment of blast cells derived from AML patients demonstrated that the drug potently killed cells. Treatment of AML blast cells with 1 mM CDDO-Me for 24 h induced apoptosis in sensitive cells as indicated by increased annexin V staining ( Figure 1 and Table 2 ). As shown in Table 2 , of 10 AML blast cell treated with CDDOMe, the majority of cells (9/10) were very sensitive to the agent (440% annexin V þ cells) and only one blast sample exhibited any significant resistance to the drug (resistance to the drug 420% annexin V þ in CDDO-Me treated CD34 þ cells compared with 6% in DMSO-treated CD34 þ cells for Patient 1). Of note, the majority of samples were derived from AML patients from poor prognosis groups (all except two were relapsed or refractory and five of nine patients where cytogentics were analyzed had multiple cytogenetic aberrations). Furthermore, CDDO-Me directly induced apoptosis in AML CD34 þ progenitor cells, as demonstrated by two-color CD34 þ /annexin V þ flow cytometry assays ( Figure 1 and Table 2 ). The effect of CDDO-Me on mitochondrial membrane potential was assessed by CMXRos staining of AML blast cells from the majority of patients (the assay was not performed for cells from Patients 1 and 2). As shown in Figure 1 , AML blast cells undergoing cell death as a result of CDDO-Me treatment displayed loss of mitochondrial membrane potential (indicated by loss of CMXRos staining) as shown in the representative patient sample (Patient 10).
CDDO-Me treatment of AML blast cells resulted in a net decrease in phosphorylated ERK levels when compared to untreated cells (Table 2 ). Relative levels of phosphorylated ERK were determined by Western analysis by comparing ERK and phosphorylated ERK levels in response to 1 mM CDDO-Me after 3 h. A representative Western depicting phosphorylated and total ERK levels in drug-resistant (Patient sample 1) and drugsensitive blast cells (Patient sample 2) is shown in Figure 2 . Consistent with a role for ERK inactivation in CDDO-Meinduced killing, the drug inhibited ERK phosphorylation in five of nine drug-sensitive blast cells and did not suppress ERK phosphorylation in the drug-resistant blast cell sample (Patient Table 1 Clinical data for patient samples with AML 
CDDO-Me promotes p38 phosphorylation and inhibition of p38 protects U937 cells from the toxic effects of CDDO-Me
Previous studies have demonstrated that regulatory mechanisms that control MAPK and SAPK cascades might overlap and may actually oppose each other. 22, 24 The possibility arises that in cases where CDDO-Me fails to inhibit ERK, perhaps a SAPK kinase such as p38 or JNK is activated. Consistent with such a mechanism, treatment of U937 cells with 0.5 mM CDDO-Me for 30 min did result in potent phosphorylation of p38 (Figure 3) . While similar treatment of U937 cells did promote mild phosphorylation of JNK, the drug had no effect on phosphorylation of c-Jun (data not shown). U937 cells were then pretreated for 24 h with either 10 mM SB203580 (a potent p38 inhibitor) or CDDO-Me promotes phosphorylation of p38 in U937 cells. U937 cells were treated with 1 mM CDDO-Me for 3 h and then lysed. Protein (5 Â 10 5 cell equivalents) was electrophoresed in 12% SDS/PAGE, transferred to nitrocellulose, and then Western analysis was performed using anti-sera to phospho-p38, p38, and GAPDH. Sample lacked CD34 + cells, so total BM cells were used.ND, Not determined.
CDDO-Me regulation of MAPK/SAPK pathways M Konopleva et al 0.1 mM SP600125 (a potent JNK inhibitor) prior to addition of 0.5 mM CDDO-Me. The SAPK inhibitors did not effect cell viability at the concentration used ( Figure 4 ). As shown in Figure 4 , both p38 and JNK inhibitors protected U937 cells from the cytotoxic effects of CDDO-Me. However, the degree of protection by p38 inhibition was highly significant (P ¼ 0.03), while JNK inhibition was not (P ¼ 0.19). The ability of the p38 inhibitor SB203580 to protect U937 cells from killing by CDDO-Me suggests a role for p38 in CDDO-Me-induced apoptosis.
CDDO-Me promotes p38 phosphorylation in AML blast cells CDDO-Me was found to induce phosphorylation of p38 in seven of eight AML blast cells (Table2 and Figure 5 ). Interestingly, three of the blast samples (Patients 3, and 9) that demonstrated an upregulation of phosphorylated p38 were CDDO-Me sensitive but displayed no change or a slight increase in phosphorylated ERK. Perhaps the activation of p38 in these cells represents a CDDO-Me-mediated apoptotic pathway that is independent of ERK. The activation of p38 (as indicated by induction of phosphorylation) suggests a potential role for the kinase in CDDO-Me-induced apoptosis in AML blast cells. As shown in Figure 5 , CDDO-Me did not induce p38 phosphorylation in blast cells from Patient 5 (which also exhibited no effect on ERK by CDDO-Me) suggesting that other molecules in addition to ERK and p38 are involved in the mechanism that regulates CDDO-Me-induced apoptosis. Still, the induction of p38 by CDDO-Me in the majority of patient samples would suggest a role for the kinase in CDDO-Meinduced cell death.
Discussion
As demonstrated in this report, CDDO-Me has the ability to suppress ERK while activating at least one SAPK kinase (ie p38).
The reciprocal inactivation of MAPK pathways with SAPK activation has previously been reported in U937 cells when these cells were treated with the sphingolipids ceramide and sphingosine. 22 Interestingly, while apoptosis is induced by both ceramide and sphingosine and the promotion of SAPK activation and suppression of ERK is observed in response to both agents, there are differences in the regulation of ERK in response to each sphingolipid. 22, 24 Sphingosine causes rapid and complete inhibition of ERK while ceramide inhibition of ERK is partial (ie two-thirds reduction in activity) and gradual. 22 It is tempting to speculate that CDDO-Me-mediated apoptosis might involve a mechanism involving sphingosine since CDDO-Me promotes near complete inhibition of ERK in a number of leukemic cell lines. 16 Loss of ERK signaling cascades can account for CDDO-Memediated cell death via the dysregulation of any number of MAPK-regulated survival pathways. [1] [2] [3] In AML cases that appear to be ERK-independent, p38 has arisen as a possible candidate for CDDO-Me-mediated apoptosis. Possible downstream targets of p38 that may be involved in the apoptotic process include numerous transcription factors (reviewed in Chen et al 3 ) and the eIF-4E kinase MNK1. 3, 25 Interestingly, MNK1 has been proposed as a convergence point between MAPK and SAPK signaling pathways. 25 It is becoming clear that the members of the MAPK and SAPK signaling cascades can participate in multiple pathways resulting in diverse effects depending on the cell type and particular stimulus involved. 26 Thus, it is not surprising that CDDO-Me might have multiple effects on signal transduction pathways involving the MAPK family. The nature of the CDDO-Me effect on the interplay between ERK and p38 is currently under investigation in our laboratory.
The present study has identified p38 as another potential target for CDDO-Me in addition to ERK. A clear picture is developing where the disruption of MAPK pathways is a critical feature of CDDO-Me-induced cell death. Furthermore, the Inhibition of JNK or p38 partially protects cells from the toxic effects of CDDO-Me. U937 cells were treated with 0.5 mM CDDO-Me for 48 h and apoptosis was determined by PS/annexin V staining as described in 'Materials and Methods'. Where appropriate, cells were pretreated for 1 h with either 10 mM SB203580 p38 inhibitor or 0.1 mM SP600125 JNK inhibitor. Error bars represent s.e. 75% based on three separate experiments. cell equivalents) was electrophoresed in 12% SDS/PAGE, transferred to nitrocellulose, and the Western analysis was performed using antisera to phospho-ERK, ERK, phospho-p38, and p38. Densitometric analysis of detected bands was performed as described in Materials and Methods and is displayed in Table 2. involvement of p38 in this process appears likely since the majority of patient blast samples exhibits activation of the kinase. The p38 inhibitor SB203580 effectively blocked the cyto-toxic effects of CDDO-Me in U937 cells. However, it remains to be determined if p38 is required for CDDO-Meinduced apoptosis in the leukemic blast cells. Still, CDDO-Me is proving efficient at inactivating prosurvival signaling regulators (ie ERK) while activating positive regulators of apoptosis (ie p38). The ability for CDDO-Me to affect multiple signaling pathways suggests that this drug will be an effective antineoplastic agent for the clinic.
